Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...
Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...
(Trinity Capital) with $50 million drawn down at closing, and access of up to an additional $80 million Cash and cash equivalents of $119.7 million, as of December 31, 2025, together with $93.5 ...
Overview of Peptide Cancer Vaccine MarketThe Global Peptide Cancer Vaccine Market is valued at USD 1.2 Billion in 2024 and is ...
Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...
Bayer is directing investor attention back to its pharmaceutical development pipeline with a strategic move that signals more than just business as usual. The f ...
An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...
Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results